These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8077767)

  • 1. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
    Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
    J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-beta.
    Liberati AM; Horisberger MA; Palmisano L; Astolfi S; Nastari A; Mechati S; Villa A; Mancini S; Arzano S; Grignani F
    J Interferon Res; 1992 Oct; 12(5):329-36. PubMed ID: 1431312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
    Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
    J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
    Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
    J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of biological effects of orally administered interferon-beta ser.
    Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC
    J Interferon Res; 1992 Dec; 12(6):411-3. PubMed ID: 1289408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in serum levels of beta 2-microglobulin, neopterin and 2',5'-oligoadenylate synthase activity during clearance of hepatitis B virus with or without acute phase in transaminases].
    Carreño García V; Hernández-Guío C; Bartolomé Nebreda J; Quiroga Estévez JA
    Rev Esp Enferm Dig; 1993 Mar; 83(3):169-75. PubMed ID: 7683894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha-induced biologic modifications in patients with chronic myelogenous leukemia.
    Liberati AM; Horisberger MA; Garofani P; De Angelis V; Ferrajoli A; Di Clemente F; Caricchi P; Adiuto D; Fedeli L; Palumbo B
    J Interferon Res; 1994 Dec; 14(6):349-55. PubMed ID: 7897254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial.
    De Leede LG; Humphries JE; Bechet AC; Van Hoogdalem EJ; Verrijk R; Spencer DG
    J Interferon Cytokine Res; 2008 Feb; 28(2):113-22. PubMed ID: 18279106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
    AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological and clinical effects of interferon-beta ser at two doses.
    Borden EC; Rinehart JJ; Storer BE; Trump DL; Paulnock DM; Teitelbaum AP
    J Interferon Res; 1990 Dec; 10(6):559-70. PubMed ID: 2086672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
    Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
    J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
    Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of natural human interleukin-2 in patients with chronic hepatitis B. Immunomodulatory and antiviral effects.
    Tilg H; Vogel W; Tratkiewicz J; Aulitzky WE; Herold M; Gruber M; Geissler D; Umlauft F; Judmaier G; Schwulera U
    J Hepatol; 1993 Sep; 19(2):259-67. PubMed ID: 8301059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effects.
    Giosuè S; Casarini M; Ameglio F; Alemanno L; Saltini C; Bisetti A
    Eur Respir J; 1996 Jan; 9(1):42-6. PubMed ID: 8834332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin.
    Chiang J; Gloff CA; Yoshizawa CN; Williams GJ
    Pharm Res; 1993 Apr; 10(4):567-72. PubMed ID: 8483840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.
    García-García I; González-Delgado CA; Valenzuela-Silva CM; Díaz-Machado A; Cruz-Díaz M; Nodarse-Cuní H; Pérez-Pérez O; Bermúdez-Badell CH; Ferrero-Bibilonia J; Páez-Meireles R; Bello-Rivero I; Castro-Odio FR; López-Saura PA;
    BMC Pharmacol; 2010 Nov; 10():15. PubMed ID: 21092287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.